top of page

NEOFYL® is derived from human umbilical cord tissue and it is intended as a cushioning agent for homologous supplementation.

NeFyl stem cell relief and repair therapy logo.
NeoFyll exosome relief and repair therapy.

Advantages:

  • Wharton’s Jelly does not exhibit an immune reaction or rejection and is considered “immune privileged”.  
     

  • Our proprietary BioRetain™ process does not alter the original tissue’s function for providing physical support and cushioning.

Features:

  • NEOFYL® is minimally manipulated to preserve the endogenous components of Wharton’s Jelly.
     

  • Wharton’s Jelly provides cushioning, support and lubrication, and is the only tissue allograft which has the structure to perform all of these functions.

Product Information

NEOFYL® is a perinatal tissue-derived allograft. It is designated as a Human Cell, Tissue, and Cellular and Tissue-Based Product (HCT/P) by the U.S. Food and Drug Administration (FDA), is minimally manipulated, and is produced in accordance with the FDA regulations for Good Tissue Practices (21 CFR 1270, 1271).

Start your journey today with a Free Consultation

Let us help you find a the right provider that aligns with your health and wellness goals.

Start your journey today with a Free Consultation

Let us help you find a the right provider that aligns with your health and wellness goals.

bottom of page